Company intelligence / Profile preview
OM Pharma
- Ownership
- Private
- Employees
- ~438
- Development stage
- Other
Overview
OM Pharma has a nearly century-long history as a Swiss-based biopharmaceutical company specializing in the prevention of recurrent respiratory and urinary tract infections using proprietary bacterial lysate immunotherapies. Its marketed products are available in over 100 countries. The company also develops small molecule drugs for vascular diseases and maintains an active R&D pipeline targeting immune-related and neoplastic conditions. Its core technology—bacterial lysates—has robust clinical backing for infection prevention. The company remains independent with headquarters and manufacturing in Geneva.
- Therapeutic areas
- CardiovascularOphthalmologyEndocrinologyWomen's HealthInfectious Diseases
- Modalities
- Bacterial lysates (immunotherapeutics)Small molecules
- Industry
- Biotech
Drug pipeline
18 assets17 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on OM Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OM Pharma.